Clinical Trial

KAP TB in Senior Management Officials of Companies With Increased Silica Exposure

Study acronym: KAP TB
Completed
View on ClinicalTrials.gov →
Summary
The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight. The sample was drawn from companies registered under the Zambia Chamber of Commerce and Industry (ZACCI), focusing on those with known silica dust exposure. Each company was asked to provide one or two senior officials to participate. A total of 118 individuals completed the survey. Data collection was carried out using a self-administered electronic questionnaire developed in line with WHO recommendations for TB KAP surveys. The questionnaire contained 28 mandatory closed-ended questions: 7 on knowledge, 8 on attitudes, and 13 on practices (with 5 practice questions excluded from scoring as they were programmatic). Responses were validated by three medical doctors, and scoring was based on correct answers. Knowledge, attitude, and practice scores were categorized into "poor" or "good" using mean or median cutoffs depending on distribution. Logistic regression was applied to explore associations between participant characteristics and KAP outcomes.
Trial Details
NCT Number NCT07749872
Lead Sponsor Centre for Infectious Disease Research in Zambia
Conditions TB - Tuberculosis, Silicosis, Occupational Exposure, Occupational Health
Enrollment 118 participants
Start Date 2022-02-02
Primary Completion 2022-10-15 (estimated)
Study Completion 2023-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-06